Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity
Arch. endocrinol. metab. (Online)
; 65(4): 421-427, July-Aug. 2021. tab, graf
Article
in English
| LILACS
| ID: biblio-1339104
Responsible library:
BR1.1
ABSTRACT
ABSTRACT Objective:
To evaluate the effect of beinaglutide on weight loss and plasma protein patterns of inflammation/obesity relevant cytokines and biomarkers. Materials andmethods:
This study involved 36 adult patients with a body mass index (BMI) of ≥ 24 kg/m2 and T2DM. Beinaglutide was administered for three months. Changes in body weight, fasting plasma glucose (FPG) level, 2 h postprandial plasma glucose (2h-PG) level, glycosylated hemoglobin (HbA1c) level, BMI and visceral and subcutaneous fat areas were measured at baseline and after three months of treatment. In addition, relevant inflammation/obesity cytokines and biomarkers were measured.Results:
After three months, beinaglutide treatment led to significant changes, including in body weight, BMI, FPG level, HbA1c level, visceral and subcutaneous fat areas. In addition, serpin E1, leptin, C-reaction protein (CRP) and tumor necrosis factor-α (TNF-α) also decreased significantly. The plasma protein concentrations of CRP (Log2 transformed) were found to be positively correlated with the percentage of weight loss (R = 0.514 and p-value = 0.021).Conclusion:
Beinaglutide treatment resulted in weight loss, plasma glucose control and anti-inflammatory effects in patients with T2DM and overweight/obesity.
Full text:
Available
Collection:
International databases
Database:
LILACS
Main subject:
Diabetes Mellitus, Type 2
Limits:
Adult
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Arch. endocrinol. metab. (Online)
Journal subject:
Endocrinology
/
Metabolism
Year:
2021
Document type:
Article
Affiliation country:
China
Institution/Affiliation country:
Shanghai Benemae Pharmaceutical Corporation/CN
/
The First Affiliated Hospital of Datong University/CN